<DOC>
	<DOCNO>NCT02694978</DOCNO>
	<brief_summary>To evaluate safety 1.020 g IV ferumoxytol compare 1.500 g IV Ferric Carboxymaltose ( FCM ) .</brief_summary>
	<brief_title>A Phase III Safety Study Ferumoxytol Compared Ferric Carboxymaltose Treatment Iron Deficiency Anemia ( IDA )</brief_title>
	<detailed_description>To assess incidence moderate severe hypersensitivity reaction , include anaphylaxis , moderate severe hypotension .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Subjects IDA intravenous iron treatment indicate define : Subjects document hemoglobin &lt; 12.0 g/dL female &lt; 14.0 g/dL male within 60 day dose And Subjects document TSAT ≤20 % Ferritin ≤100 ng/mL within 60 day dose Documented history unsatisfactory oral iron therapy oral iron tolerate , oral iron consider medically inappropriate ( per oral iron history questionnaire ) Subject capable understanding comply protocol requirement available duration study All subject ( male female ) childbearing potential sexually active agree routinely use adequate contraception randomization throughout duration study Known hypersensitivity reaction component ferumoxytol FCM History allergy IV iron History multiple drug allergy Subjects dialysis dependent CKD Hemoglobin ≤7.0 g/dL Female subject pregnant , intend become pregnant , breastfeeding , positive serum/urine pregnancy test willing use effective contraceptive precaution study ( include female childbearing potential partner male subject )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>iron deficiency anemia</keyword>
	<keyword>IDA</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>ferric carboxymaltose</keyword>
	<keyword>FCM</keyword>
	<keyword>Injectafer</keyword>
</DOC>